-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Biogen, Raises Price Target to $240

Benzinga·07/30/2026 20:31:49
Listen to the news
UBS analyst Michael Yee maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $225 to $240.